FDA Approves Vaccine to Prevent Respiratory Syncytial Virus

RSV Vaccine Protects High-Risk Individuals from Severe Illness

The Food and Drug Administration (FDA) has approved a vaccine manufactured by GlaxoSmithKline (GSK) to prevent respiratory syncytial virus (RSV) in adults aged 60 years and older. RSV is a common respiratory virus that usually causes mild cold-like symptoms, but it can be serious, especially for young children and older adults.

Vaccine Efficacy

Clinical trials showed that the GSK vaccine reduced the incidence of RSV-associated lower respiratory tract disease by 80% in adults aged 60 years and older. The vaccine was also found to be well-tolerated, with no serious safety concerns.

Importance for High-Risk Individuals

RSV is a leading cause of hospitalization and death in older adults. The GSK vaccine offers a new tool to protect this vulnerable population from severe RSV illness. The vaccine is recommended for all adults aged 60 years and older, especially those with chronic health conditions.

Availability

The GSK RSV vaccine is now available in the United States. Adults aged 60 years and older should discuss vaccination with their healthcare provider.